Cloperastine hydrochloride CAS 14984-68-0
Introduction:Basic information about Cloperastine hydrochloride CAS 14984-68-0, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Cloperastine hydrochloride Basic information
| Product Name: | Cloperastine hydrochloride |
| Synonyms: | 1-(2-((p-chloro-alpha-phenylbenzyl)oxy)ethyl)-piperidinhydrochloride;1-(2-(p-cloro-alpha-fenilbenzilossi)etil)piperidinacloridrato;2-piperidinoethylp-chlorobenzhydryletherhydrochloride;cloperastinacloridrato;ht11;hustazol;4-CHLOROBENZHYDRYL 2-[1-PIPERIDYL]-ETHYL ETHER HYDROCHLORIDE;CHLOPERASTINE HYDROCHLORIDE |
| CAS: | 14984-68-0 |
| MF: | C20H25Cl2NO |
| MW: | 366.32 |
| EINECS: | 239-067-8 |
| Product Categories: | |
| Mol File: | 14984-68-0.mol |
Cloperastine hydrochloride Chemical Properties
| Melting point | 147.9° |
| storage temp. | Inert atmosphere,Room Temperature |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| form | Solid |
| color | White to Off-White |
| Merck | 14,2395 |
| Major Application | forensics and toxicology pharmaceutical (small molecule) veterinary |
| InChI | InChI=1S/C20H24ClNO.ClH/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22;/h1,3-4,7-12,20H,2,5-6,13-16H2;1H |
| InChIKey | UNPLRYRWJLTVAE-UHFFFAOYSA-N |
| SMILES | C(OCCN1CCCCC1)(C1C=CC=CC=1)C1=CC=C(Cl)C=C1.Cl |
| CAS DataBase Reference | 14984-68-0(CAS DataBase Reference) |
Safety Information
| Hazard Codes | Xn |
| Risk Statements | 22 |
| Safety Statements | 36 |
| WGK Germany | 3 |
| RTECS | TM6491500 |
| HS Code | 2933.39.9200 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Acute Tox. 4 Oral |
| Uses | Antitussive;'Histamine antagonist |
| Uses | Cloperastine Hydrochloride is an anti-tussive drug as an over-the-counter cold medicine. |
| Definition | ChEBI: Cloperastine hydrochloride is a diarylmethane. |
| in vivo | In the anesthetized guinea pigs, Cloperastine at a therapeutic dose of 1 mg/kg prolonged the QT interval and monophasic?action potential (MAP) duration without affecting PR interval or QRS width[1]. |
